Please complete or attach patient	Follow-up Number	BADBIR ID									
BAD Biologic Intervent	ions Register Clinical Fol	low-Up Questionnaire									
BIOLOGIC /	IMMUNOMODULATOR COHO	ORT ONLY:									
Biologic Therapy											
Since the patient's last follow up have their been any changes to their biologic / immunomodulatory therapy? Yes If yes, please record all changes for biologic No											
Batch Dose / Drug Number unit Fre	equency Date started ddmmyy	Date of final dose <i>ddmmyy</i> *Stop reason									
*Stop reasons: (1) Inefficacy (2) Remissi	on (3) Adverse Events (4) Inefficacy a	and Adverse Events (5) Patient Non-									
Compliance (6) Titration (7) Financial											
If infliximab or Stelara please provide the ac	dministration dates	HUMIRA ONLY: Did the patient receive									
d d	m m y y mg/kg	the 80mg loading dose?									
		Yes No No									
		TALTZ ONLY: Was the recommended opening schedule followed? (i.e. 160mg at									
		week 0, 80mg at weeks 2, 4, 6, 8, 10, and 12) Yes No Currently Unknown									
		(will advise at next follow-up) COSENTYX ONLY: Was the recommended									
Were any scheduled doses missed? For Taltz/Cosentyx was there any		opening schedule followed? (i.e. 300mg at									
deviation from the opening schedule?	ord an adverse event if appropriate*	weeks 0, 1, 2, 3 & 4) Yes No Currently Unknown (will advise at next follow-up)									
If yes please record details:											
Conventional Therapy	ONVENTIONAL COHORT ONLY	:									
Since the patient's last follow up have there been any changes to their systemic therapy? Yes											
If yes, please record all changes for systemic agents:											
Drug Dose / unit Frequency	Date started ddmmyy Date	e of final dose <i>ddmmyy</i> *Stop reason									
*Stop reasons: (1) Inefficacy (2) Remissi Compliance (6) Titration (7) Financial	•										
St. J.											
Since the patient's last follow up have they s		No No Biologics Only box at the top of this page.									
Version 9 01/08/2017 p.1 of 4 If yes please en	ter details of their biologic therapy in the	biologics only box at the top of this page.									

	Yes	No. of Courses	No. of	Cumulative	Data Known to
UV Therapy Details	163	No. of Courses	Treatments	Dose (J/cm ²)	be Accurate?
Broadband UVB				,	
Narrowband UVB					
TOTAL BODY PUVA					
Oral PUVA					
Topical PUVA					
HAND AND FOOT PUVA Oral PUVA					
Topical PUVA					
UVA 1	-				
Since the patient's last fo Please list all changes bel for psoriasis except for tag	l ow: (please	note we do not need o			
Drug	srommas and	Start date	Stop dat	e Are the	se dates estimated?
lues Please comp	olete the fo	ollowing laboratory va	alues (recent i.e. w	ithin last 6 months):
		llowing laboratory va	alues (recent i.e. w Result	ithin last 6 months):
Please comp	RY VALUES		-):
Please comp	RY VALUES	(dL)	-		FUP7+:
Please comp	RY VALUES in count (g/ ount (x10 ⁹ /	(dL)	-		
LABORATOR Haemoglobi White cell co	RY VALUES in count (g/ ount (x10 ⁹ / int (x10 ⁹ /L)	(dL)	-		FUP7 + : Lab Value
Please comp LABORATOF Haemoglobi White cell cou	RY VALUES in count (g/ ount (x10 ⁹ / int (x10 ⁹ /L) µmol/L)	(dL)	-		FUP7 + : Lab Value
Please comp LABORATOF Haemoglobi White cell complete council counci	RY VALUES in count (g/ ount (x10 ⁹ / int (x10 ⁹ /L) µmol/L) se ALT (U/L	(dL)	-		FUP7 + : Lab Value

Yes

Since the patients last follow-up have they had any UV therapy?

HDL (mmol/L)

UV Therapy

5															Þ
ersion 9 01	7	6	л	4	ω	2	1	Code						Event No.	Adverse Events Since c entry F experic events
Version 9 01/08/2017 p.3 of 4	Medically Important Event	Was in any way life threatening	Congenital malformation	Significant loss of function or disability	IV Anti-biotics/virals/fungals	Hospitalisation	Death	e SAE Classification						Short description of event (please record diagnosis if available)	Exents Since date of last data entry has your patient experienced any adverse events)? Yes No
	ent	eatening	on .	ion or disability	ngals			cation						Descri	An <u>adverse event</u> A <u>serious adverse</u> Please enter deta
 Drug misuse, abuse, overdose and medication 	 Melanoma / Skin Cancer (inc. Bowens Disease) 	 Malignancy (not inc. skin) 	 Lymphoproliferative Disease 	 Hepatitis B Reactivation 	 Cerebrovascular Accident (CVA) 	serious neutropenia	 Aplastic anaemia, pancytopaenia or 	If any of the events you have listed include any of the following, ar						Description of event	An <u>adverse event</u> (AE) is defined as any medically untoward even A <u>serious adverse event</u> (SAE) is defined by the classifications in t Please enter details of <u>ALL</u> adverse events (both serious and non-
nd medication	owens Disease)						ia or	ude any of the follow						Start date	ally untoward e classification th serious and
	• Ser	• Ser	• Pul	• Pro	• Pre	Cor	• My	_						Estimated?	event o
	ious Hep	Serious Congestive Heart Failure	Pulmonary Embolism	gressive	Pregnancy	Coronary Disease	Myocardial Infarction/Acute	ent of Spe						Stop date	t occurring in he box below serious) from
	atic Dy:	gestive	Embolis	Multifoc		isease	Infarcti	cial Inte						Stop Date Estimated?	ng in a elow
	sfunctio	Heart F	m	al Leuk			ion/Acu	rest (ESI)	m =	B =	B =	B =	B =	Is the event ongoing?	patie his fol
	Serious Hepatic Dysfunction/Failure	ailure		Progressive Multifocal Leukoencephalopathy			te	Event of Special Interest (ESI) form needs to be completed:	If 'Yes' Name of Biologic:	If 'Yes' Name of Biologic:	If 'Yes' Name of Biologic:	If 'Yes' Name of	If "Yes" Name of	Is the event related to biologic therapy? Yes, No or Possibly Not required for conventional cohort patients	t occurring in a patient whether or he box below serious) from this follow-up period
	•	• 5	• 5	•	• 50	• 5	• 5	comple						Yellow Card Sent?	or not
	Tuberculosis (Not Latent)	Surgery (Overnight Hospitalisation Only)	Serious Skin Reaction	Serious Psoriasis Flare (Overnight Hospitalisation Only)	Serious Lupus/Lupus like illness	Serious Infection (excl. TB)	Serious Hypersensitivity Reaction	ted:	If 'Hospitalisation' Admission Date: Discharge Date:	If 'Hospitalisation' Admission Date: Discharge Date:	If 'Hospitalisation' Admission Date: Discharge Date:	If 'Hospitalisation' Admission Date: Discharge Date:	If 'Hospitalisation' Admission Date:	Is the event a SAE? If yes please select code (see below)	t occurring in a patient whether or not related to any treatment or medication he box below serious) from this follow-up period
	nt)	talisation Only)		Overnight Hospital	te illness	ТВ)	y Reaction							Is the event an ESI? If yes please select from list (see below)	eatment or mo
				'isation Only)					Resolved Resolved Not Resolved USequelae UNot Resolved USequelae Unknown Death Death	Resolved Resolved Not Resolved Not Resolved Not Resolved Not Resolved Death	Resolved Resolved W/ Sequelae Not Resolved Sequelae Unknown Death	Resolved Resolved W/ Sequelae Not Resolved INDIANOWN IND	Resolved	Outcome of the event?	edication

Current Disease	Severity										
	Please indicate the current disease	severity (i.	e. at the time the pati	ent started the new drug)							
	BSA		Only if the patient h	as pustular psoriasis,							
	Date of	BSA/.	/								
	Please details of all PASI's that have been completed since the patients last follow-up.										
	PASI Date of PASI Psoriasis Global Assessment										
			-								
					_						
					_						
					-						
				<u>I</u>	J						
	Psoriasis Global Asse	ssment sco	ore: • Severe								
			• Moderate t	o severe							
			Moderate								
			• Mild								
			Almost clea	r							
			• Clear								
	Has the patient been diagnosed wit	h psoriatic	arthritis by a rheuma	tologist? Yes No	· 🗀						
	if this is a new diagnosis please reme	mber to ada	l this as an adverse even	t							
Additional Info	mation										
	What is the patient's <u>curr</u>	<u>ent</u> weight	and waist circumfere								
			Weight	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	UP9 + : Veight / Waist						
		Waist c	ircumference		ot required						
if the patier	nt is under 16 year of age on the da	te of this fo	ollow-up, please provi	de a <u>neight</u> measurement:	cm						
Patient Follow-	up Questionnaire		1	1							
	Occupation questionnaire should DLQI	Qus	Lifestyle Qus CAGE	If paediatric patient:							
also be com	pleted containing: DLQI Euro(Qol	*HAQ	cDLQ	*cHAQ						
FUP 7+:				EQ-5D-y	спац						
Patient 0	Patient Questionnaire is <u>not required</u> (*Only if patient has a rheumatologist's										
Signature Signature											
Please sign and date below:											
	Clinician's signature:		Date:								

Version 9 01/08/2017 p.4 of 4